The funding will also allow ReCode to advance its PCD and CF programs into the clinic, and further develop its genetic medicine delivery platform to deliver additional treatments—from gene correction modalities and small interfering RNA (siRNA) therapies—to a wider range of target cell types both predictably and programmable. The financing will also enable ReCode’s planned expansion to its own 30,000-square-foot facility in Menlo Park, CA . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge